ArticleRisk analysis : an official publication of the Society for Risk Analysis2019
Information Hazards in Biotechnology.
Article in Risk analysis : an official publication of the Society for Risk Analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Defining the molecular interaction between influenza hemagglutinin and MHC-II.bioRxiv : the preprint server for biology · 2026Article
- Functional and antigenic constraints on the Nipah virus fusion protein.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Red-teaming as an imperative for strengthening synthetic nucleic acid screening.Frontiers in bioengineering and biotechnology · 2026Review
- Functional and antigenic constraints on the Nipah virus fusion protein.bioRxiv : the preprint server for biology · 2026Article
- Dual-use capabilities of concern of biological AI models.PLoS computational biology · 2025Article
- Article
- Deep mutational scanning of H5 hemagglutinin to inform influenza virus surveillance.PLoS biology · 2024Article
- Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex.Immunity · 2024Article
- Five Things Not to Do When Discovering a Biosecurity Vulnerability.Applied biosafety : journal of the American Biological Safety Association · 2024Article
- Practical Questions for Securing Nucleic Acid Synthesis.Applied biosafety : journal of the American Biological Safety Association · 2024Article
- Developing a Common Global Baseline for Nucleic Acid Synthesis Screening.Applied biosafety : journal of the American Biological Safety Association · 2024Article
- Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex.bioRxiv : the preprint server for biology · 2024Article
- Biosecurity in an age of open science.PLoS biology · 2022Article
- Governing biotechnology to provide safety and security and address ethical, legal, and social implications.Frontiers in genetics · 2022Article
- Principles of synthetic biology.Essays in biochemistry · 2021Article
- Article
- Dual-Use Quickscan: A Web-Based Tool to Assess the Dual-Use Potential of Life Science Research.Frontiers in bioengineering and biotechnology · 2021Article
- Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future Biosurveillance.Health securityArticle
- Motivating Proactive Biorisk Management.Health securityReview
- Who Should We Fear More: Biohackers, Disgruntled Postdocs, or Bad Governments? A Simple Risk Chain Model of Biorisk.Health securityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
With the advance of biotechnology, biological information, rather than biological materials, is increasingly the object of principal security concern. We argue that both in theory and in practice, existing security approaches in biology are poorly suited to manage hazardous biological information, and use the cases of Mousepox, H5N1 gain of function, and Botulinum toxin H to highlight these ongoing challenges. We suggest that mitigation of these hazards can be improved if one can: (1) anticipate hazard potential before scientific work is performed; (2) consider how much the new information would likely help both good and bad actors; and (3) aim to disclose information in the manner that maximally disadvantages bad actors versus good ones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.